Boston builds DES (drug-eluting stent) business with bioresorbable stent
This article was originally published in Clinica
Executive Summary
Having successfully taken on the drug-eluting stent (DES) market with Taxus Express2, Boston Scientific is wasting no time in reinforcing its arsenal with a new-generation DES. The company has made an equity investment in REVA Medical, as well as securing an exclusive option to buy the private, San Diego-based developer of bioresorbable stents. Details of the agreement were not disclosed.